WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

Raccontata daendpoints.newsbiopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo1 g fa

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

originale
endpoints.news1 g fa

Veradermics declares first efficacy win in women for hair loss drug

Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due 2027.

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 15 luglio 2026·endpoints.news

    Veradermics declares first efficacy win in women for hair loss drug

    Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due 2027.

  2. giovedì 16 luglio 2026·biopharmadive.com

    Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

    The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female…